TY - JOUR
T1 - The risk of new-onset type 2 diabetes and the influence of risk factors among men with prostate cancer in the Danish Diet, Cancer, and Health study
AU - Widding, Jeppe Lyngbye
AU - Barsøe, Monika
AU - Ammitzbøll, Gunn
AU - Dalton, Susanne Oksbjerg
AU - Olsen, Maja Halgren
AU - Levinsen, Anne Katrine Graudal
AU - Brasso, Klaus
AU - Laurberg, Tinne
AU - Tjønneland, Anne
AU - Larsen, Signe Benzon
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025
Y1 - 2025
N2 - Purpose: To investigate the risk of new-onset type 2 diabetes mellitus (T2DM) in men with and without prostate cancer (PCa) and the influence of cardiometabolic risk factors. Furthermore, we examined the association between first-line androgen deprivation therapy (ADT) and the risk of T2DM in a subpopulation of men with PCa. Methods: In the Danish prospective Diet, Cancer, and Health cohort, we identified 2604 men with PCa and 9340 PCa-free men for comparison. We used Cox regression models to investigate the hazard ratios (HR) of T2DM from the date of diagnosis. Results: During 100,408 person-years at risk, 887 men were diagnosed with T2DM. Overall, no increased hazard of T2DM was observed in men with PCa compared to PCa-free men, but within the first year after PCa diagnosis, the HR of T2DM was 70% increased. In all men, the HRs for T2DM increased markedly with overweight/obesity, while comorbidity was associated with a pronounced increased HR in men with PCa. Within the PCa subpopulation, no association between ADT and T2DM was observed. Conclusion: Men with PCa have no overall increased risk of being diagnosed with T2DM compared to PCa-free men, despite an increased risk within the first year following cancer diagnosis, likely affected by increased surveillance. Implications for Cancer Survivors: Overall, survivors of PCa should not be more concerned about T2DM than PCa-free men; first-line treatment does not change the overall risk of T2DM in survivors of PCa. However, cardiometabolic risk factors require awareness to mitigate the risk of T2DM.
AB - Purpose: To investigate the risk of new-onset type 2 diabetes mellitus (T2DM) in men with and without prostate cancer (PCa) and the influence of cardiometabolic risk factors. Furthermore, we examined the association between first-line androgen deprivation therapy (ADT) and the risk of T2DM in a subpopulation of men with PCa. Methods: In the Danish prospective Diet, Cancer, and Health cohort, we identified 2604 men with PCa and 9340 PCa-free men for comparison. We used Cox regression models to investigate the hazard ratios (HR) of T2DM from the date of diagnosis. Results: During 100,408 person-years at risk, 887 men were diagnosed with T2DM. Overall, no increased hazard of T2DM was observed in men with PCa compared to PCa-free men, but within the first year after PCa diagnosis, the HR of T2DM was 70% increased. In all men, the HRs for T2DM increased markedly with overweight/obesity, while comorbidity was associated with a pronounced increased HR in men with PCa. Within the PCa subpopulation, no association between ADT and T2DM was observed. Conclusion: Men with PCa have no overall increased risk of being diagnosed with T2DM compared to PCa-free men, despite an increased risk within the first year following cancer diagnosis, likely affected by increased surveillance. Implications for Cancer Survivors: Overall, survivors of PCa should not be more concerned about T2DM than PCa-free men; first-line treatment does not change the overall risk of T2DM in survivors of PCa. However, cardiometabolic risk factors require awareness to mitigate the risk of T2DM.
KW - Androgen deprivation therapy
KW - Cancer survivorship
KW - Late effects
KW - Nested case–control
KW - Register study
UR - https://www.scopus.com/pages/publications/105002597367
U2 - 10.1007/s11764-025-01776-7
DO - 10.1007/s11764-025-01776-7
M3 - Journal article
C2 - 40234323
AN - SCOPUS:105002597367
SN - 1932-2259
JO - Journal of Cancer Survivorship
JF - Journal of Cancer Survivorship
ER -